Dynavax Techno…
ProfileJobs (20)

Dynavax Technologies

Suggest Edit
    • Healthcarebiotechdrug developmentpharma

    Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The Company develops immunotherapies based on cutting-edge Toll-Like Receptor biology and its ability to modulate the immune system.

    Dynavax Technologies Corporation's clinical-stage product candidates include HBsAg-1018 is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response designed to provide protection against hepatitis B; and the Company's lead cancer immunotherapy compound, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells to antigen-presenting cells. 

    Revenue(FY, 2017)
    $327 K
    Market capitalization(2018-12-04)
    $664.5 M

    Employee Rating

    3.3More
    TypePublic
    HQBerkeley, US
    Founded1996
    Size (employees)251 (est)
    Websitedynavax.com
    Dynavax Technologies was founded in 1996 and is headquartered in Berkeley, US
    Report incorrect company information

    Viewing summary data as a guest

    Sign up for free to see all data

    Key People/Management at Dynavax Technologies

    Steven N. Gersten

    Steven N. Gersten

    Vice President and General Counsel
    Robert Janssen

    Robert Janssen

    Chief Medical Officer and Senior Vice President, Clinical Development
    Michael S. Ostrach

    Michael S. Ostrach

    Senior Vice President, Chief Financial Officer and Chief Business Officer
    Show more

    Dynavax Technologies Office Locations

    Dynavax Technologies has an office in Berkeley
    Berkeley, (HQ)
    100 2929 Seventh Street
    Show all (1)
    Report incorrect company information

    Dynavax Technologies Financials and Metrics

    Dynavax Technologies Revenue

    Dynavax Technologies's revenue was reported to be $327 k in FY, 2017
    USD

    Revenue (Q3, 2018)

    		1.5m

    Net income (Q3, 2018)

    		(40.5m)

    EBIT (Q3, 2018)

    		(38.9m)

    Market capitalization (4-Dec-2018)

    		664.5m

    Closing stock price (4-Dec-2018)

    		10.6

    Cash (30-Sep-2018)

    		38.7m

    EV

    		726.1m
    Dynavax Technologies's current market capitalization is $664.5 m.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		11.3m11.0m4.1m11.0m327.0k

    Revenue growth, %

    		(2%)(63%)173%

    General and administrative expense

    		25.9m17.4m22.2m37.3m27.4m

    R&D expense

    		50.9m84.6m86.9m84.5m65.0m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Revenue

    		3.5m3.0m2.2m627.0k1.6m1.2m942.0k2.6m162.0k148.0k105.0k53.0k165.0k1.3m1.5m

    General and administrative expense

    		5.8m4.2m4.1m4.1m4.9m5.1m5.5m8.2m9.2m11.8m6.5m5.6m6.0m16.9m15.7m15.8m

    R&D expense

    		11.8m13.2m23.6m28.1m22.2m19.7m24.1m20.1m22.8m23.2m16.3m14.8m16.4m19.0m16.3m16.8m

    Operating expense total

    		18.5m17.5m27.9m32.3m27.1m24.8m29.6m28.2m31.9m35.0m25.6m20.4m22.4m38.5m39.4m40.4m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		23.1m49.5m44.8m24.3m26.6m

    Accounts Receivable

    		1.6m727.0k1.4m

    Inventories

    		1.4m4.1m2.4m6.8m312.0k

    Current Assets

    		192.4m127.4m199.9m89.6m198.0m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Cash

    		12.2m26.8m17.0m19.7m14.7m36.5m103.0m38.9m24.8m23.0m21.5m37.7m20.1m36.1m28.7m38.7m

    Accounts Receivable

    		2.2m1.7m1.3m727.0k909.0k657.0k1.2m1.2m

    Inventories

    		550.0k5.1m12.5m

    Current Assets

    		79.8m181.7m160.6m134.9m102.0m97.9m224.3m170.7m147.1m117.5m89.7m132.2m197.1m255.4m226.3m198.8m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(66.7m)(90.7m)(106.8m)(112.4m)(95.2m)

    Depreciation and Amortization

    		1.3m1.4m1.4m2.3m3.2m

    Inventories

    		677.0k(2.7m)1.6m560.0k(312.0k)

    Accounts Payable

    		(657.0k)(523.0k)1.2m1.2m(1.9m)
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

    Net Income

    		(53.7m)(13.8m)(38.6m)(68.4m)(26.2m)(49.8m)(79.9m)(27.0m)(56.0m)(90.7m)(25.3m)(45.6m)(67.7m)(39.0m)(78.4m)(118.9m)

    Depreciation and Amortization

    		986.0k339.0k680.0k1.0m634.0k958.0k402.0k946.0k1.6m789.0k1.7m2.5m823.0k1.7m2.5m

    Inventories

    		(238.0k)(4.8m)(12.1m)

    Accounts Payable

    		(877.0k)154.0k112.0k3.3m3.3m648.0k273.0k658.0k1.6m704.0k(2.1m)(2.9m)(1.5m)349.0k1.6m2.4m
    show all
    USDY, 2018

    EV/EBIT

    		-18.7 x

    EV/CFO

    		-7.4 x

    Debt/Equity

    		1 x

    Debt/Assets

    		0.4 x

    Financial Leverage

    		2.4 x
    Show all financial metrics

    Dynavax Technologies Operating Metrics

    FY, 2016

    Patents (Foreign)

    		260

    Patents Pending

    		40

    Phase III Trials Products

    		1

    Preclinical Phase Products

    		2
    Show all operating metrics

    Dynavax Technologies Revenue Breakdown

    Embed Graph

    Dynavax Technologies revenue breakdown by business segment: 8.0% from Service and license revenue, 88.5% from Collaboration revenue and 3.5% from Other

    Report incorrect company information

    Competitors

    Kiniksa Pharmaceuticals
    Healthcare - Public
    Sartorius Stedim BioOutsource
    Healthcare - Subsidiary
    Neurosearch
    Healthcare - Public
    Biogen
    Healthcare - Public
    Compare competitors

    Dynavax Technologies Company Life and Culture

    Report incorrect company information
    Download PDF

     Dynavax Technologies Frequently Asked Questions

    • When was Dynavax Technologies founded?

      Dynavax Technologies was founded in 1996.

    • Who are Dynavax Technologies key executives?

      Dynavax Technologies's key executives are Steven N. Gersten, Robert Janssen and Michael S. Ostrach.

    • How many employees does Dynavax Technologies have?

      Dynavax Technologies has 251 employees.

    • What is Dynavax Technologies revenue?

      Latest Dynavax Technologies annual revenue is $327 k.

    • What is Dynavax Technologies revenue per employee?

      Latest Dynavax Technologies revenue per employee is $1.3 k.

    • Who are Dynavax Technologies competitors?

      Competitors of Dynavax Technologies include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.

    • Where is Dynavax Technologies headquarters?

      Dynavax Technologies headquarters is located at 100 2929 Seventh Street, Berkeley.

    • Where are Dynavax Technologies offices?

      Dynavax Technologies has an office in Berkeley.

    • How many offices does Dynavax Technologies have?

      Dynavax Technologies has 1 office.